2220-PUB: Renal Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus in a Real-World Setting: The Renal-WECAN Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2220-PUB
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
Renal Outcomes ◽  
Real World Setting

1127-P: Real-World Clinical Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus: The Real-WECAN Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1127-P
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Outcomes ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
The Real

scholarly journals Glycated Hemoglobin (Hba1c) Control In Patients with Type 2 Diabetes Mellitus (T2dm) Treated with Canagliflozin In a real-world setting

2015 ◽  
Vol 18 (3) ◽  
pp. A57 ◽  
Author(s):  
P. Lefebvre ◽  
D. Pilon ◽  
M. Robitaille ◽  
M. Lafeuille ◽  
W. Chow ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Glycated Hemoglobin ◽  
Real World Setting ◽  
Hba1c Control
Sign in / Sign up

Export Citation Format

Share Document